CytRx Highlights Orphazyme’s Update on Planned NDA Resubmission for Arimoclomol in Niemann-Pick Disease Type C

LOS ANGELES–(BUSINESS WIRE)–CytRx Corporation (OTCQB: CYTR) (“CytRx” or the “Company”), a biopharmaceutical company focused on research and development for the oncology and neurodegenerative disease categories, today highlighted Orphazyme A/S’s (NASDAQ: ORPH) ("Orphazyme") announced update on the process and anticipated timelines for resubmission of its New Drug Application ("NDA") to the…